Immunome Inc. Contracts & Agreements

Form of Morphimmune, Inc. Indemnification Agreement (Filed With SEC on August 8, 2023)

Forms of Restricted Stock Purchase Agreement, Stock Option Agreement and Early Exercise Stock Purchase Agreement under the Morphimmune, Inc. 2020 Equity Incentive Plan (Filed With SEC on August 8, 2023)

Morphimmune, Inc. 2020 Equity Incentive Plan (Filed With SEC on August 8, 2023)

Master License Agreement, by and between Morphimmune, Inc. and Purdue Research Foundation, dated as of January 19, 2021, as modified pursuant to that certain email by Max Rosett... (Filed With SEC on August 8, 2023)

Master Sponsored Research Agreement, by and among Morphimmune, Inc., Purdue Research Foundation, and Purdue University, dated February 1, 2022, as amended by that certain... (Filed With SEC on August 8, 2023)

Agreement and Plan of Merger and Reorganization, dated June 29, 2023, by and among Immunome, Inc., Ibiza Merger Sub, Inc. and Morphimmune, Inc (Filed With SEC on June 29, 2023)

Form of Immunome, Inc. Stockholder Support Agreement, dated June 29, 2023 (Filed With SEC on June 29, 2023)

Form of Morphimmune, Inc. Stockholder Support Agreement, dated June 29, 2023 (Filed With SEC on June 29, 2023)

Form of Lock-Up Agreement, dated June 29, 2023 (Filed With SEC on June 29, 2023)

Form of Subscription Agreement, dated June 29, 2023 (Filed With SEC on June 29, 2023)

Employment Agreement, dated June 28, 2023, by and between Immunome, Inc. and Clay B. Siegall, Ph.D (Filed With SEC on June 29, 2023)

Modification of Contract between the Company and the Department of Defense, United States of America, dated January 4, 2023 (Filed With SEC on March 16, 2023)

Amended and Restated Employment Agreement of Matthew Robinson effective June 16, 2022 (Filed With SEC on March 16, 2023)

Employment Agreement between the Company and Dennis Giesing effective April 7, 2021 (Filed With SEC on March 16, 2023)

Letter Agreement by and between the registrant and the Whitehead Institute for Biomedical Research, dated November 17, 2022 (Filed With SEC on March 16, 2023)

Amendment #2 to the License Agreement by and between the registrant and Arrayjet Limited, dated December 30, 2022 (Filed With SEC on March 16, 2023)

Description of Securities (Filed With SEC on March 16, 2023)

Letter to Holders of Series B Warrants to Purchase Shares of Common Stock (Filed With SEC on September 2, 2022)

Second Amended and Restated Non-Employee Director Compensation Policy, effective as of June 15, 2022 (Filed With SEC on August 5, 2022)

Modification of Contract between the Company and the Department of Defense, United States of America, dated March 18, 2022 (portions of this exhibit (indicated by asterisks) have... (Filed With SEC on May 12, 2022)

Immunome, Inc. Annual Employee Bonus Plan (Filed With SEC on March 28, 2022)

Description of Securities (Filed With SEC on March 28, 2022)

Amended and Restated Non-Employee Director Compensation Policy (Filed With SEC on November 15, 2021)

Fourth Amendment to Second Amended and Restated Management Services Agreement, dated June 1, 2021, by and between the Company and Broadband Capital Partners LLC (Filed With SEC on August 16, 2021)

Second Amended and Restated Employment Agreement, dated August 1, 2021, by and between the Company and Dr. Morin (Filed With SEC on August 5, 2021)

Modification of Contract between the Company and the Department of Defense, United States of America, dated May 19, 2021 (portions of this exhibit (indicated by asterisks) have... (Filed With SEC on May 20, 2021)

Engagement Letter, dated April 9, 2021, as amended on April 25, 2021, by and among Immunome, Inc. and Ladenburg Thalmann & Co. Inc (Filed With SEC on April 26, 2021)

Securities Purchase Agreement, dated April 26, 2021, by and among Immunome, Inc. and the Purchasers signatory thereto (Filed With SEC on April 26, 2021)

Form of Warrant (Filed With SEC on April 26, 2021)

Employment Letter Agreement between the Company and Corleen M. Roche (Filed With SEC on April 20, 2021)

Master Services Agreement, between the Company and Abzena (San Diego) Inc dated December 14, 2020 (Filed With SEC on March 25, 2021)

Employment Agreement between the Company and Sandra G. Stoneman effective October 19, 2020 (Filed With SEC on March 25, 2021)

Description of Securities (Filed With SEC on March 25, 2021)

Separation Agreement and General Release between the Company and Richard Fitzgerald, dated December 1, 2020 (Filed With SEC on December 4, 2020)

Second Amendment to License Agreement by and between the registrant and Thomas Jefferson University, dated July 28, 2020 (Filed With SEC on November 16, 2020)

Amended and Restated Employment Agreement by and between the registrant and Michael J. Morin, dated September 23, 2020 (Filed With SEC on September 24, 2020)

Amended and Restated Employment Agreement by and between the registrant and Purnanand D. Sarma, dated September 23, 2020 (Filed With SEC on September 24, 2020)

Non-Employee Director Compensation Policy (Filed With SEC on September 24, 2020)

Offer Letter Agreement by and between the registrant and Richard F. Fitzgerald, dated September 18, 2020 (Filed With SEC on September 24, 2020)

2020 Employee Stock Purchase Plan (Filed With SEC on September 24, 2020)

Forms of Stock Option Grant Notice, Option Agreement, RSU Award Grant Notice and Notice of Exercise for the 2020 Equity Incentive Plan (Filed With SEC on September 24, 2020)

2020 Equity Incentive Plan (Filed With SEC on September 24, 2020)

Form of Amendment to 2020 Series A Preferred Stock Warrants (Filed With SEC on September 24, 2020)

Form of Common Stock Certificate (Filed With SEC on September 24, 2020)

Form of Underwriting Agreement (Filed With SEC on September 9, 2020)